Poster presentations a reproducible model system, resulting in enterocutaneous fistulas 2-4w later. XGR samples were analysed by immunohistochemistry staining (IHC) for EMT-, immune cell-and cell death markers. Results: IHC staining of the XGR fistulas showed similar expression patterns for various EMT markers (e.g. SNAIL1) like in human CD fistula samples. The overexpression of the mesenchymal marker alphasmooth muscle actin confirmed the hypothesis that EMT plays a critical role for the fistula development in the XGR mouse model, too. Moreover, collagen staining showed that the inflammatory regions were associated with fibrosis suggesting extracellular matrix remodelling. The inflammatory response up-and downstream to the XGR fistula tracts mainly consisted of human CD45+ cells, but only very few murine CD45+ cells. Further characterisation revealed CD4+ T cells as predominant cell type in the fistulating samples. Also strong expression levels of human CD68+ cells were found in the XGR fistulas. The overexpression of TNF α in the XGR fistulas samples emphasises the importance of this mouse model, since this most likely represents a novel platform for the evaluation of new therapies for CD fistulas in vivo. Positive TUNEL and cleaved caspase-3 IHC staining in the XGR fistula samples suggest apoptosis playing a role here, too.
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Serum markers predict outcome to ustekinumab in patients with refractory Crohn's disease and provide insides in the mechanism of action Background: Ustekinumab (UST), targeting the IL-12/23 shared p40 subunit, was recently approved by FDA and EMA for treatment of moderate-to-severe Crohn's disease (CD). The aim of this study was to identify potential predictive immunological biomarkers for response, which may guide treatment strategies with ustekinumab. Methods: Serum samples of 36 CD patients (73% female, median disease duration 15.9 years), all refractory to anti-TNF therapy and vedolizumab and with baseline endoscopic active disease, were prospectively collected prior to UST initiation. Patients received UST 6 mg/kg IV at induction, with subcutaneous UST 90 mg q8w thereafter. Endoscopic response was assessed at week 24, and defined as ≥ 50% SES-CD decrease. Proteomic analysis (OLINK) was performed on baseline serum samples. Additionally, inflamed ileal (n = 10) and colonic (n = 17) biopsies, prior to UST therapy, were collected. Mucosal total RNA was isolated, and next-generation sequencing performed. Differentially gene expression was evaluated by DESeq R package. Results: Patients with (n = 7) and without (n = 29) endoscopic response at week 24 had a similar baseline inflammatory burden, reflected by similar median faecal calprotectin (1800 vs. 1721 µg/g, p = 0.22), C-reactive protein (20.3 vs. 9.4 mg/l, p = 0.36) and IL-6 (p = 0.37, fold change (FC)=1.06) before start of UST. Baseline endoscopic activity was much higher in patients responding to UST, compared with nonresponders (median SES-CD 21 vs. 13, p < 0.001). Several proteins significantly correlated with baseline SES-CD, but only one protein, CD40 (r = 0.87, p = 0.05), also significantly differed between responders and non-responders before UST initiation (p = 0.029 with corresponding FC 1.46). At baseline, CCL11 also varied between responders and nonresponders (p = 0.06, FC 1.45), but did not correlate with baseline SES-CD (p = 0.97). ROC-statistics showed a significant area under the curve (81.5%, p = 0.011) for prediction of response based on the combination of both. On mucosal level, a non-significant increase in both CD40 and CD40L could be observed in colonic biopsies of responders at baseline (FC 1.6 and 1.5, respectively). Ileal biopsies also expressed increased CD40L in responders (FC 2.0). Conclusions: Two potential predictive biomarkers for response to UST were identified, which need validation in larger and independent cohorts. Because it has been shown that CD40/CD40L-triggering of dendritic cells induces expression of high levels of IL-23 and not IL-12, low CD40 levels in non-responders suggest another mechanism, apart from the IL-12/23 pathway, driving inflammation in these patients. These findings may aid in individualised selection of biological agents in Crohn's disease, and provide mechanisms of primary (non-)response to UST.
